| Next 10 |
VERU News and Press, Veru Inc.
-
Veru's Sabizabulin showed superlative results in critically ill COVID patients. No other drug has been able to achieve this. If the company manages this well, we are looking at a blockbuster potential drug. For further details see: Veru: Where Big Pharma Failed To Tread ...
-
MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at ...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks are trending as the market’s losses only widen Recession fears remain a growing concern amid global economic shortcomings Vertex Energy (NASDAQ: VTNR ) tops this week’s list as ...
-
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDA...
-
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...
-
The shares of Veru Inc. (NASDAQ:VERU) have surged ~20% in the pre-market Friday after Jefferies raised its price target citing a favorable response from the FDA as the oncology-focused pharma company plans to seek U.S. authorization for its COVID-19 therapy, sabizabulin. On Wednesda...
-
Call End: Veru Inc. (VERU) Q2 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Office...
-
The following slide deck was published by Veru Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Veru Inc. 2022 Q2 - Results - Earnings Call Presentation
-
Dutch Bros (BROS) -39% on Q1 earnings release. Eargo (EAR) -24%. Beyond Meat (BYND) -28% on Q1 earnings release. Evaxion Biotech (EVAX) -17% on Q1 earnings release. Senseonics Holdings (SENS) -12%. ironSource (IS) -11% on Q1 earnings rele...
-
Veru press release (NASDAQ:VERU): Q2 GAAP EPS of -$0.18 misses by $0.06. Revenue of $13.03M (-2.3% Y/Y) misses by $2.23M. Gross margin increased to 86% of net revenues from 82% of net revenues, a record high compared to any prior quarter Operating loss was $11.8 million versus $1.5 million CE...
Stock Information
MENU
VERU
VERU Quote
VERU Short
VERU News
VERU Articles
Get VERU Alerts
News, Short Squeeze, Breakout and More Instantly...
-
MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at ...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks are trending as the market’s losses only widen Recession fears remain a growing concern amid global economic shortcomings Vertex Energy (NASDAQ: VTNR ) tops this week’s list as ...
-
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDA...
x
